REVTORPYK (gedatolisib) — Topline data
Q4 2026
The company expects to provide updated clinical data and additional visibility into its mCRPC development strategy during the fourth quarter of 2026.Source filing
CELC biotech catalysts & pipeline
CELCUITY INC · Data as of 2026-09-08
Upcoming catalysts
REVTORPYK (gedatolisib) — Topline data
Late 2028
We expect topline data for this group to be available by the end of 2028.Source filing
REVTORPYK (gedatolisib) — Topline data
in 2030
We expect topline data for this group to be available in 2030.Source filing